Cargando…
Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future
Of the 207 Serious Adverse Events (SAEs) following treatment with Mectizan(® )(ivermectin, Merck, Sharpe & Dohme) that were reported from 1989 to 2001 through the passive SAE surveillance system required of all onchocerciasis mass treatment programs, 65 were cases of 'Probable' or ...
Autor principal: | Twum-Danso, Nana AY |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2147656/ https://www.ncbi.nlm.nih.gov/pubmed/14975064 http://dx.doi.org/10.1186/1475-2883-2-S1-S7 |
Ejemplares similares
-
A Framework for Decision-Making for Mass Distribution of Mectizan(®) in Areas Endemic for Loa loa
por: Addiss, David G, et al.
Publicado: (2003) -
Collateral Impact of Community-Directed Treatment with Ivermectin (CDTI) for Onchocerciasis on Parasitological Indicators of Loa loa Infection
por: Nana-Djeunga, Hugues C., et al.
Publicado: (2020) -
“Test and not treat” for onchocerciasis control in a Loa
loa endemic area
por: Kamgno, Joseph, et al.
Publicado: (2017) -
Albendazole-related Loa Loa encephalopathy
por: Métais, Alice, et al.
Publicado: (2021) -
Assessing Hypoendemic Onchocerciasis in Loa loa Endemic Areas of Southeast Nigeria
por: Rakers, Lindsay J., et al.
Publicado: (2020)